Errichetti, E. et al. 2024. Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial. Acta Dermato-Venereologica. 104, (Sep. 2024), adv41053. DOI:https://doi.org/10.2340/actadv.v104.41053.